| 1 | Development and Multicenter Case–Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction | 4.5 | 26 | Citations (PDF) |
| 2 | MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer | 10.8 | 25 | Citations (PDF) |
| 3 | 3D multiplexed tissue imaging reconstruction and optimized region of interest (ROI) selection through deep learning model of channels embedding | 1.9 | 12 | Citations (PDF) |
| 4 | Segmentation of cellular ultrastructures on sparsely labeled 3D electron microscopy images using deep learning | 1.9 | 5 | Citations (PDF) |
| 5 | Efficient semi-supervised semantic segmentation of electron microscopy cancer images with sparse annotations | 1.9 | 0 | Citations (PDF) |
| 6 | Targeted Nanoparticle for Co‐delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+ Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis | 7.3 | 47 | Citations (PDF) |
| 7 | An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer | 5.3 | 49 | Citations (PDF) |
| 8 | A multi-encoder variational autoencoder controls multiple transformational features in single-cell image analysis | 3.1 | 50 | Citations (PDF) |
| 9 | A framework for multiplex imaging optimization and reproducible analysis | 3.1 | 54 | Citations (PDF) |
| 10 | A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs | 19.7 | 43 | Citations (PDF) |
| 11 | Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment | 10.8 | 190 | Citations (PDF) |
| 12 | Computational multiplex panel reduction to maximize information retention in breast cancer tissue microarrays | 1.9 | 14 | Citations (PDF) |
| 13 | Ex Vivo Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics | 2.8 | 16 | Citations (PDF) |
| 14 | Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics | 4.9 | 51 | Citations (PDF) |
| 15 | The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2-positive breast cancer | 3.7 | 33 | Citations (PDF) |
| 16 | Chemokine signaling in cancer-stroma communications | 2.1 | 22 | Citations (PDF) |
| 17 | In Situ Tumor Vaccination with Nanoparticle Co‐Delivering CpG and STAT3 siRNA to Effectively Induce Whole‐Body Antitumor Immune Response | 17.5 | 57 | Citations (PDF) |
| 18 | Relevance of circulating hybrid cells as a non-invasive biomarker for myriad solid tumors | 2.7 | 64 | Citations (PDF) |
| 19 | Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA | 3.4 | 17 | Citations (PDF) |
| 20 | Genomic Alterations during the
In Situ
to Invasive Ductal Breast Carcinoma Transition Shaped by the Immune System | 2.0 | 39 | Citations (PDF) |
| 21 | Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies | 4.9 | 25 | Citations (PDF) |
| 22 | Oligonucleotide conjugated antibody strategies for cyclic immunostaining | 2.7 | 35 | Citations (PDF) |
| 23 | Development and implementation of the SUM breast cancer cell line functional genomics knowledge base | 4.7 | 11 | Citations (PDF) |
| 24 | SHIFT: speedy histological-to-immunofluorescent translation of a tumor signature enabled by deep learning | 2.7 | 68 | Citations (PDF) |
| 25 | Transcriptional signatures in histologic structures within glioblastoma tumors may predict personalized drug sensitivity and survival | 0.7 | 7 | Citations (PDF) |
| 26 | VISTA: VIsual Semantic Tissue Analysis for pancreatic disease quantification in murine cohorts | 2.7 | 9 | Citations (PDF) |
| 27 | Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines | 28.4 | 65 | Citations (PDF) |
| 28 | RESTORE: Robust intEnSiTy nORmalization mEthod for multiplexed imaging | 3.1 | 37 | Citations (PDF) |
| 29 | Oligonucleotide conjugated antibodies permit highly multiplexed immunofluorescence for future use in clinical histopathology | 1.7 | 24 | Citations (PDF) |
| 30 | Predicting primary site of secondary liver cancer with a neural estimator of metastatic origin | 0.9 | 9 | Citations (PDF) |
| 31 | PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer | 6.5 | 68 | Citations (PDF) |
| 32 | Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity | 1.6 | 18 | Citations (PDF) |
| 33 | Using Microarrays to Interrogate Microenvironmental Impact on Cellular Phenotypes in Cancer | 0.2 | 19 | Citations (PDF) |
| 34 | Circulating tumor DNA dynamics using patient-customized assays are associated with outcome in neoadjuvantly treated breast cancer | 0.8 | 34 | Citations (PDF) |
| 35 | Targeting mitochondria in cancer therapy could provide a basis for the selective anti-cancer activity | 1.5 | 24 | Citations (PDF) |
| 36 | DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters | 4.4 | 58 | Citations (PDF) |
| 37 | Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting | 4.4 | 243 | Citations (PDF) |
| 38 | Simultaneous Multicolor Single-Molecule Tracking with Single-Laser Excitation via Spectral Imaging | 1.5 | 60 | Citations (PDF) |
| 39 | MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection | 1.9 | 36 | Citations (PDF) |
| 40 | Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes | 3.5 | 93 | Citations (PDF) |
| 41 | Implementing a comprehensive translational oncology platform: from molecular testing to actionability | 4.8 | 43 | Citations (PDF) |
| 42 | Transcriptional Programming of Normal and Inflamed Human Epidermis at Single-Cell Resolution | 4.4 | 298 | Citations (PDF) |
| 43 | Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer | 10.8 | 173 | Citations (PDF) |
| 44 | Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival | 8.1 | 301 | Citations (PDF) |
| 45 | Molecular Cytogenetics Guides Massively Parallel Sequencing of a Radiation-Induced Chromosome Translocation in Human Cells | 1.1 | 15 | Citations (PDF) |
| 46 | Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment | 1.5 | 20 | Citations (PDF) |
| 47 | Context Specificity in Causal Signaling Networks Revealed by Phosphoprotein Profiling | 3.5 | 49 | Citations (PDF) |
| 48 | Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform | 1.2 | 59 | Citations (PDF) |
| 49 | Circulating-tumor DNA as an early detection and diagnostic tool | 2.4 | 102 | Citations (PDF) |
| 50 | HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer | 4.5 | 125 | Citations (PDF) |
| 51 | Activity of distinct growth factor receptor network components in breast tumors uncovers two biologically relevant subtypes | 5.9 | 17 | Citations (PDF) |
| 52 | Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis | 4.4 | 581 | Citations (PDF) |
| 53 | Combating subclonal evolution of resistant cancer phenotypes | 10.8 | 157 | Citations (PDF) |
| 54 | Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer | 1.2 | 40 | Citations (PDF) |
| 55 | Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound | 4.4 | 33 | Citations (PDF) |
| 56 | Quantitative, in situ analysis of mRNAs and proteins with subcellular resolution | 2.7 | 10 | Citations (PDF) |
| 57 | Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics | 3.8 | 45 | Citations (PDF) |
| 58 | Quantitating morphological changes in biological samples during scanning electron microscopy sample preparation with correlative super-resolution microscopy | 1.5 | 67 | Citations (PDF) |
| 59 | Genome co-amplification upregulates a mitotic gene network activity that predicts outcome and response to mitotic protein inhibitors in breast cancer | 3.4 | 17 | Citations (PDF) |
| 60 | Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment | 6.0 | 25 | Citations (PDF) |
| 61 | FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer | 5.2 | 151 | Citations (PDF) |
| 62 | IL-10 and integrin signaling pathways are associated with head and neck cancer progression | 2.1 | 49 | Citations (PDF) |
| 63 | Inferring causal molecular networks: empirical assessment through a community-based effort | 13.1 | 240 | Citations (PDF) |
| 64 | Reconstruction of Gene Regulatory Networks Based on Repairing Sparse Low-Rank Matrices | 2.6 | 2 | Citations (PDF) |
| 65 | Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics | 2.0 | 280 | Citations (PDF) |
| 66 | Genome-wide perturbations by miRNAs map onto functional cellular pathways, identifying regulators of chromatin modifiers | 2.3 | 4 | Citations (PDF) |
| 67 | Disentangling Multidimensional Spatio-Temporal Data into Their Common and Aberrant Responses | 1.5 | 1 | Citations (PDF) |
| 68 | Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease | 1.5 | 106 | Citations (PDF) |
| 69 | Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy | 4.5 | 113 | Citations (PDF) |
| 70 | Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway | 5.2 | 275 | Citations (PDF) |
| 71 | Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer | 11.9 | 188 | Citations (PDF) |
| 72 | The consensus molecular subtypes of colorectal cancer | 22.6 | 4,911 | Citations (PDF) |
| 73 | Exome sequencing of desmoplastic melanoma identifies recurrent NFKBIE promoter mutations and diverse activating mutations in the MAPK pathway | 14.1 | 264 | Citations (PDF) |
| 74 | Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination | 5.2 | 173 | Citations (PDF) |
| 75 | Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer | 1.5 | 23 | Citations (PDF) |
| 76 | Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient Tumor Methylome? | 1.5 | 23 | Citations (PDF) |
| 77 | Reply to Colorectal cancer classification based on gene expression is not associated with FOLFIRI response | 22.6 | 5 | Citations (PDF) |
| 78 | Copy Number Gain of hsa-miR-569 at 3q26.2 Leads to Loss of TP53INP1 and Aggressiveness of Epithelial Cancers | 28.4 | 52 | Citations (PDF) |
| 79 | Exact reconstruction of gene regulatory networks using compressive sensing | 2.5 | 38 | Citations (PDF) |
| 80 | Causal network inference using biochemical kinetics | 3.2 | 53 | Citations (PDF) |
| 81 | CUL4A Induces Epithelial–Mesenchymal Transition and Promotes Cancer Metastasis by Regulating ZEB1 Expression | 2.6 | 186 | Citations (PDF) |
| 82 | Endocytic trafficking of laminin is controlled by dystroglycan and disrupted in cancers | 1.7 | 24 | Citations (PDF) |
| 83 | Identification of gene regulation patterns underlying both oestrogen- and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells | 2.8 | 17 | Citations (PDF) |
| 84 | A community effort to assess and improve drug sensitivity prediction algorithms | 19.7 | 784 | Citations (PDF) |
| 85 | Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections | 8.1 | 228 | Citations (PDF) |
| 86 | Joint estimation of multiple related biological networks | 0.8 | 14 | Citations (PDF) |
| 87 | A robust prognostic signature for hormone-positive node-negative breast cancer | 5.9 | 19 | Citations (PDF) |
| 88 | Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges | 5.8 | 392 | Citations (PDF) |
| 89 | Metrics other than potency reveal systematic variation in responses to cancer drugs | 9.1 | 332 | Citations (PDF) |
| 90 | Identification and Quantification of AKT Isoforms and Phosphoforms in Breast Cancer Using a Novel Nanofluidic Immunoassay | 3.2 | 33 | Citations (PDF) |
| 91 | A colorectal cancer classification system that associates cellular phenotype and responses to therapy | 22.6 | 918 | Citations (PDF) |
| 92 | Expanding the Diversity of Imaging-Based RNAi Screen Applications Using Cell Spot Microarrays | 1.1 | 8 | Citations (PDF) |
| 93 | Modeling precision treatment of breast cancer | 4.8 | 285 | Citations (PDF) |
| 94 | Bayesian Inference of Signaling Network Topology in a Cancer Cell Line | 3.2 | 99 | Citations (PDF) |
| 95 | Optimization-based Inference for Temporally Evolving Networks with Applications in Biology | 0.7 | 7 | Citations (PDF) |
| 96 | Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells? | 1.8 | 17 | Citations (PDF) |
| 97 | What are we learning from the cancer genome? | 54.3 | 53 | Citations (PDF) |
| 98 | Integrating biological knowledge into variable selection: an empirical Bayes approach with an application in cancer biology | 2.5 | 20 | Citations (PDF) |
| 99 | Subtype and pathway specific responses to anticancer compounds in breast cancer | 5.2 | 453 | Citations (PDF) |
| 100 | Genetic Differences in Transcript Responses to Low-Dose Ionizing Radiation Identify Tissue Functions Associated with Breast Cancer Susceptibility | 1.5 | 30 | Citations (PDF) |
| 101 | Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence | 2.6 | 186 | Citations (PDF) |
| 102 | 'Omic approaches to preventing or managing metastatic breast cancer | 3.4 | 23 | Citations (PDF) |
| 103 | Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy | 22.6 | 1,869 | Citations (PDF) |
| 104 | Radiosensitivity profiles from a panel of ovarian cancer cell lines exhibiting genetic alterations in p53 and disparate DNA-dependent protein kinase activities | 2.2 | 22 | Citations (PDF) |
| 105 | A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers | 2.4 | 222 | Citations (PDF) |
| 106 | Exon-Level Microarray Analyses Identify Alternative Splicing Programs in Breast Cancer | 2.0 | 124 | Citations (PDF) |
| 107 | p27Kip1 Mediates Addiction of Ovarian Cancer Cells to MYCC (c-MYC) and Their Dependence on MYC Paralogs | 1.3 | 21 | Citations (PDF) |
| 108 | Breast cancer genomes — form and function | 2.4 | 56 | Citations (PDF) |
| 109 | The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer | 3.4 | 129 | Citations (PDF) |
| 110 | Picomolar sensitivity MRI and photoacoustic imaging of cobalt nanoparticles | 5.2 | 176 | Citations (PDF) |
| 111 | A Primer on Regression Methods for Decoding cis-Regulatory Logic | 1.9 | 14 | Citations (PDF) |
| 112 | Sparse combinatorial inference with an application in cancer biology | 3.2 | 19 | Citations (PDF) |
| 113 | A systems analysis of the chemosensitivity of breast cancer cells to the polyamine analogue PG-11047 | 4.4 | 36 | Citations (PDF) |
| 114 | HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment | 1.8 | 302 | Citations (PDF) |
| 115 | Translating insights from the cancer genome into clinical practice | 30.7 | 284 | Citations (PDF) |
| 116 | Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer | 2.1 | 186 | Citations (PDF) |
| 117 | Crosstalk between Aurora-A and p53: Frequent Deletion or Downregulation of Aurora-A in Tumors from p53 Null Mice | 28.4 | 85 | Citations (PDF) |
| 118 | Magellan: A Web Based System for the Integrated Analysis of Heterogeneous Biological Data and Annotations; Application to DNA Copy Number and Expression Data in Ovarian Cancer | 1.3 | 4 | Citations (PDF) |
| 119 | A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes | 28.4 | 2,934 | Citations (PDF) |
| 120 | Genomic and transcriptional aberrations linked to breast cancer pathophysiologies | 28.4 | 1,181 | Citations (PDF) |
| 121 | The melanocyte differentiation program predisposes to metastasis after neoplastic transformation | 14.1 | 419 | Citations (PDF) |
| 122 | A conditional feedback loop regulates Ras activity through EphA2 | 28.4 | 245 | Citations (PDF) |
| 123 | Array comparative genomic hybridization with cyanin
cis
-platinum-labeled DNAs | 2.7 | 19 | Citations (PDF) |
| 124 | Reconstruction of functionally normal and malignant human breast tissues in mice | 5.2 | 741 | Citations (PDF) |
| 125 | A screen for genes that suppress loss of contact inhibition: Identification of
ING4
as a candidate tumor suppressor gene in human cancer | 5.2 | 140 | Citations (PDF) |
| 126 | In situ analyses of genome instability in breast cancer | 14.1 | 348 | Citations (PDF) |
| 127 | Absence of telomerase and shortened telomeres have minimal effects on skin and pancreatic carcinogenesis elicited by viral oncogenes | 28.4 | 19 | Citations (PDF) |
| 128 | Genome Amplification of Chromosome 20 in Breast Cancer | 1.8 | 105 | Citations (PDF) |
| 129 | The genetics and genomics of cancer | 14.1 | 514 | Citations (PDF) |
| 130 | Chromosome aberrations in solid tumors | 14.1 | 740 | Citations (PDF) |
| 131 | End-sequence profiling: Sequence-based analysis of aberrant genomes | 5.2 | 121 | Citations (PDF) |
| 132 | Stromal-epithelial interactions in the progression of ovarian cancer: influence and source of tumor stromal cells | 2.0 | 59 | Citations (PDF) |
| 133 | Assembly of microarrays for genome-wide measurement of DNA copy number | 14.1 | 936 | Citations (PDF) |
| 134 | Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas | 14.1 | 273 | Citations (PDF) |
| 135 | Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival | 5.2 | 91 | Citations (PDF) |
| 136 | Selective Inactivation of p53 Facilitates Mouse Epithelial Tumor Progression without Chromosomal Instability | 1.5 | 57 | Citations (PDF) |
| 137 | Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene | 14.1 | 564 | Citations (PDF) |
| 138 | HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA | 5.2 | 68 | Citations (PDF) |
| 139 | Genome changes and gene expression in human solid tumors | 2.2 | 176 | Citations (PDF) |
| 140 | Quantitative mRNA Expression Analysis from Formalin-Fixed, Paraffin-Embedded Tissues Using 5′ Nuclease Quantitative Reverse Transcription-Polymerase Chain Reaction | 1.9 | 282 | Citations (PDF) |
| 141 | PIK3CA is implicated as an oncogene in ovarian cancer | 14.1 | 1,061 | Citations (PDF) |
| 142 | The Stromal Proteinase MMP3/Stromelysin-1 Promotes Mammary Carcinogenesis | 23.4 | 1,030 | Citations (PDF) |
| 143 | Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation | 14.1 | 1,231 | Citations (PDF) |
| 144 | Efficient, interactive, and three-dimensional segmentation of cell nuclei in thick tissue sections 1998, 31, 275-286 | | 46 | Citations (PDF) |
| 145 | Molecular cytogenetic analysis of consistent abnormalities at 8q12-q22 in breast cancer 1998, 22, 105-113 | | 44 | Citations (PDF) |
| 146 | Genetic analysis using genomic representations | 5.2 | 83 | Citations (PDF) |
| 147 | FISH Probes for Mouse Chromosome Identification | 2.0 | 58 | Citations (PDF) |
| 148 | Subregional Localization of 21 Chromosome 7-Specific Expressed Sequence Tags (ESTs) by FISH Using Newly Identified YACs and P1s | 2.0 | 1 | Citations (PDF) |
| 149 | 20q gain associates with immortalization: 20q13.2 amplification correlates with genome instability in human papillomavirus 16 E7 transformed human uroepithelial cells | 5.2 | 124 | Citations (PDF) |
| 150 | Evidence of a dominant transcriptional pathway which regulates an undifferentiated and complete metastatic phenotype | 5.2 | 17 | Citations (PDF) |
| 151 | A t-statistic for objective interpretation of comparative genomic hybridization (CGH) profiles 1997, 28, 183-190 | | 58 | Citations (PDF) |
| 152 | High sensitivity, high resolution physical mapping by fluorescence in situ hybridization on to individual straightened DNA molecules | 1.6 | 6 | Citations (PDF) |
| 153 | Identification of novel regions of altered DNA copy number in small cell lung tumors | 1.7 | 93 | Citations (PDF) |
| 154 | Computer image analysis of comparative genomic hybridization | 0.0 | 254 | Citations (PDF) |
| 155 | Quantitative DNA fiber mapping | 2.1 | 100 | Citations (PDF) |
| 156 | Comparative Genomic Hybridization | 1.4 | 14 | Citations (PDF) |
| 157 | Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors | 1.7 | 1,225 | Citations (PDF) |
| 158 | Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. | 5.2 | 669 | Citations (PDF) |
| 159 | Cloning and Characterization of EagI YACs from Human Chromosome 21 | 2.0 | 3 | Citations (PDF) |
| 160 | Factors that Determine the in vivo Dose-Response Relationship for Stable Chromosome Aberrations in A-Bomb Survivors | 1.3 | 0 | Citations (PDF) |
| 161 | High-throughput, single-particle tracking reveals nested membrane domains that dictate KRasG12D diffusion and trafficking | 1.0 | 55 | Citations (PDF) |
| 162 | Title is missing! 0 | | 1 | Citations (PDF) |
| 163 | Radiation effects research foundation—a view to the future | 2.2 | 2 | Citations (PDF) |
